Adding mitomycin to BCG as adjuvant intravesical therapy for high-risk, non–muscle-invasive bladder cancer: a randomised phase III trial

A randomised phase II trial using PSMA as a therapeutic agent and prognostic indicator in people with metastatic castration-resistant prostate cancer treated with enzalutamide.

Enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: a randomised phase III trial

Enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer: a randomised phase III trial

Denosumab and Pembrolizumab in clear cell renal carcinoma: a phase II trial

Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer

A prospective randomised multi-centre study of the impact of Ga-68 PSMA-PET/CT imaging for staging high risk prostate cancer prior to curative-intent surgery or radiotherapy

A randomised phase II trial of 177Lu-PSMA617 theranostic versus cabazitaxel in progressive metastatic castration resistant prostate cancer

A Randomised Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Us…

A Phase II Trial Of Single Agent Cabozantinib In Patients With Locally Advanced Or Metastatic Non-Clear Cell Renal Cell Carcinoma Post Immunotherapy Or Who Are Unsuitable For Immunotherapy

UNISoN: anzUp Nivo -> Ipi + Nivo Sequential Non-clear cell Proposed phase II sequential cohort trial of single agent Nivolumab, then combination Ipil…

TROG 15.03 Focal Ablative STereotactic RAdiosurgery for Cancers of the Kidney – A Phase II Clinical Trial

Developing a Patient-Reported Symptom Index for Non-muscle Invasive Bladder Cancer